Respiratory Syncytial Virus(RSV) Vaccine
In May 2023, the Food and Drug Administration (FDA) licensed two vaccines, Arexvy and Abrysvo, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in adults aged 60 years and older. However, recent findings indicate that Guillain-Barre syndrome (GBS), a rare nervous system disorder, may be more common than expected among recipients of these vaccines.
New CDC Report on GSK RSV Vaccine
The new CDC report focused on 28 cases of the syndrome in people who were vaccinated, and all but one developed symptoms within 21 days. That translated to 1.5 cases per million in people who got the GSK RSV vaccine, and five cases per million in recipients of the Pfizer shot.
CDC officials presented related findings on the RSV shots and Guillain-Barre syndrome at a February public meeting.
An estimated 3,000 to 6,000 people develop Guillain-Barre syndrome in the U.S. each year either after being infected by a virus or linked to a vaccination and in older people it is more common, according to the CDC. Most people fully recover, but some have permanent nerve damage.
Reports of a rare nervous system disorder were “more common than expected” in older U.S. adults who got the new RSV vaccines, According to a Centers for Disease Control and Prevention report released Thursday that is similar to what the organization said earlier this year.
Recommendations of CDC, GBS and FDA
The CDC and the U.S. Food and Drug Administration say they are evaluating any risks, but do not plan to change their recommendation for the RSV shots, which is that patients 60 and older should talk to their doctor and then decide whether to be vaccinated.
More than 10 million older adults have gotten either Pfizer or GSK single-dose shots since early August to protect against respiratory syncytial virus, which is a common cause of cold-like symptoms and can be dangerous for infants and older people.Health officials have estimated about two cases of Guillain-Barre syndrome in every 1 million people who receive the RSV vaccine within three weeks of getting the shot.
Conclusion
As ongoing surveillance continues, population based studies will further evaluate the risk of GBS associated with RSV vaccines. The Advisory Committee on Immunization Practices (ACIP) will use these findings to guide their recommendations. If you are in the eligible age group, consult your doctor to make an informed choice regarding RSV vaccination.
Read aslo:1) Irvine Farmers Market 4us “Great Park Certified Farmers Market: Fresh Produce and Fun
2) Breast Cancer Surviving Ladies can have Child after ASCO treatment program,2024
3) What is Dehydration, How Drinking is Helpful in Dehydration and Top 10 most Popular Drink
Read More News: Click Here
